Location:
Hartford Room, The Commons Building, 2nd
Floor, The Institute of Living/Hartford Hospital
200 Retreat Avenue, Hartford, CT 06106
Abstract:
Vast amounts of information about the
workings of the brain and psychiatric disorders have been compiled over the past
two decades. This information is opening up new approaches to assessment,
treatment, and ongoing clinical management of patients with psychiatric
disorders. This presentation presents an overview of the emergent
neurobiological principles that should influence cutting edge prescriptive
practices for patients experiencing common psychiatric disorders. Content will
address new understanding of such things as soft neurological signs, cortical
plasticity, hierarchical structuring, and brain neurotrophic factors. The links
between this content and the selection of medications for optimal treatment will
be discussed, along with the rational for the development of many new
psychiatric treatments, and the implications of this knowledge to the APN role.
Participants will leave this presentation with a clear idea of how to apply and
utilize neurobiological principles in every day care practice settings.
Learning Objectives:
-
The participants will be able to identify
the critical principles of advance neurobiology needed for prescriptive
clinical practice.
-
The participants will be able to
analyze the role of neurotransmitters and brain
structures in the behavioral expression of mental illness.
-
The participants will be able to
discuss the implications for prescriptive
practice of new brain findings.
References:
Wright IC, Rabe-Hesketh S, Woodruff
PW, et al. Meta-analysis of regional brain volumes in schizophrenia. Am J
Psychiatry. Jan 2000;157(1):16-25.
Sigmundsson T, Suckling J, Maier M,
et al. Structural abnormalities in frontal, temporal, and limbic regions and
interconnecting white matter tracts in schizophrenic patients with prominent
negative symptoms. Am J Psychiatry. Feb 2001;158(2):234-43.
Coyle
JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev
Psychiatry. Jan-Feb 1996;3(5):241-53.
American Psychiatric Association. Diagnostic
and Statistical Manual of Mental Disorders (DSM-IV-TR). 4th
ed. Washington, DC: American Psychiatric Press; 2000.
Brown AS, Begg MD, Gravenstein S,
Schaefer CA, Wyatt RJ, Bresnahan M, et al. Serologic evidence of prenatal
influenza in the etiology of schizophrenia. Arch Gen Psychiatry. Aug 2004;61
(8):774-80.
Cummings
JL, Gosenfeld LF, Houlihan JP, McCaffrey T. Neuropsychiatric disturbances
associated with idiopathic calcification of the basal ganglia. Biol
Psychiatry. May 1983;18(5):591-601.
Rosebush PI, MacQueen GM, Clarke
JT, et al. Late-onset Tay-Sachs disease presenting as catatonic schizophrenia:
diagnostic and treatment issues. J Clin Psychiatry. Aug 1995;56(8):347-53.
Pope HG Jr, Katz DL. Psychiatric
and medical effects of anabolic-androgenic steroid use. A controlled study of
160 athletes. Arch Gen Psychiatry. May 1994;51(5):375-82.
Reuler JB, Girard DE, Cooney
TG. Current concepts. Wernicke''s encephalopathy. N Engl J Med. Apr
18 1985;312(16):1035-9.
Hagg S, Spigset O, Soderstrom
TG. Association of venous thromboembolism and clozapine. Lancet. Apr
1 2000;355(9210):1155-6.
Thomassen R, Vandenbroucke JP,
Rosendaal FR. Antipsychotic drugs and venous thromboembolism. Lancet. Jul
15 2000;356(9225):252.
Newcomer JW. Metabolic
considerations in the use of antipsychotic medications: a review of recent
evidence. J Clin Psychiatry. Suppl 1 2007;68:20-7.
Baldessarini RJ, Frankenburg FR. Clozapine.
A novel antipsychotic agent. N Engl J Med. Mar 14 1991;324(11):746-54.
McGlashan
TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, et al. Randomized,
double-blind trial of olanzapine versus placebo in patients prodromally
symptomatic for psychosis. Am J Psychiatry. May 2006;163:790-9.
Aronson SC, Ayres VE. Depression: A
treatment algorithm for the family physician. Hospital Physician. 2000.
Brown C, Schulberg HC. Diagnosis
and treatment of depression in primary medical care practice: the application of
research findings to clinical practice. J Clin Psychol. Apr 1998;54(3):303-14.
Charlifue S, Gerhart K. Changing
psychosocial morbidity in people aging with spinal cord injury. NeuroRehabilitation. 2004;19(1):15-23.
Delgado PL, Miller HL, Salomon RM,
et al. Tryptophan-depletion challenge in depressed patients treated with
desipramine or fluoxetine: implications for the role of serotonin in the
mechanism of antidepressant action. Biol Psychiatry. Jul
15 1999;46(2):212-20.
Elkin I, Shea MT, Watkins JT, et
al. National Institute of Mental Health Treatment of Depression Collaborative
Research Program. General effectiveness of treatments. Arch Gen Psychiatry. Nov 1989;46(11):971-82;
discussion 983.
Katon W, Von Korff M, Lin E, et
al. Collaborative management to achieve treatment guidelines. Impact on
depression in primary care. JAMA. Apr 5 1995;273(13):1026-31.
Leon AC, Olfson M, Broadhead WE, et
al. Prevalence of mental disorders in primary care. Implications for screening. Arch
Fam Med. Oct 1995;4(10):857-61.
Murray
ML, Wong IC, de Vries CS. Treating major depression in children and adolescents:
research is needed into safer and more effective drugs. BMJ. Feb
28 2004;328(7438):524-5.
Nelson JC. Augmentation strategies
for treatment of unipolar major depression. Mod Probl Pharmacopsychiatry. 1997;25:34-55.
Pascual-Leone A, Rubio B, Pallardo
F, Catala MD. Rapid-rate transcranial magnetic stimulation of left dorsolateral
prefrontal cortex in drug-resistant depression. Lancet. Jul
27 1996;348(9022):233-7.
Persad E. Electroconvulsive therapy
in depression. Can J Psychiatry. Mar 1990;35(2):175-82.
Sheikh RM, Weller EB, Weller RA. Prepubertal
depression: diagnostic and therapeutic dilemmas. Curr Psychiatry Rep. Apr 2006;8(2):121-6.
Solomon DA, Leon AC, Maser JD, et
al. Distinguishing bipolar major depression from unipolar major depression with
the screening assessment of depression-polarity (SAD-P). J Clin Psychiatry. Mar 2006;67(3):434-42.
Spitz R. Anaclitic depression: An
inquiry into the genesis of psychiatric conditions in early
childhood. Psychoanalytic Study of the Child. 1946;Vol 2:313-342.
Thase ME. Evaluating antidepressant
therapies: remission as the optimal outcome. J Clin Psychiatry. 2003;64 Suppl
13:18-25.
Thomas SA, Friedmann E, Wimbush F,
Schron E. Psychological factors and survival in the cardiac arrhythmia
suppression trial (CAST): a reexamination. Am J Crit Care. Mar 1997;6(2):116-26.
Bibliography prepared by
the IOL Medical Library. Call 545-7276 for information.
Books
Clark DL et al. The Brain
and Behavior: An Introduction to Behavioral Neuroanatomy. Cambridge
University Press, 2005. WL 300 C592b.
Stahl SM. Essential
Psychopharmacology: Neuroscientific Basis and Practical Applications, Second
Edition. Cambridge University Press, 2000. WM 402 S781e.
Articles
<1> Howland RH.
Glutamate-modulating drugs & the treatment of mental disorders. [Review] [33
refs] Journal of Psychosocial Nursing & Mental Health Services. 45(1):11-4,
2007 Jan.
<2> Askland K. Parsons
M. Toward a biaxial model of "bipolar" affective disorders: spectrum phenotypes
as the products of neuroelectrical and neurochemical alterations. [Review] [190
refs] Journal of Affective Disorders. 94(1-3):15-33, 2006 Aug.
<3> Howland RH.
Personalized drug therapy with pharmacogenetics--part 2: pharmacodynamics.
[Review] [17 refs] Journal of Psychosocial Nursing & Mental Health Services.
44(2):13-6, 2006 Feb.
<4> Arnsten AF. Li BM.
Neurobiology of executive functions: catecholamine influences on prefrontal
cortical functions. [Review] [95 refs] Biological Psychiatry. 57(11):1377-84,
2005 Jun 1.
<5> Keltner NL. Kelley FJ.
The ABCs of psychopharmacology. Perspectives in Psychiatric Care.
39(4):169-73, 2003 Oct-Dec. (ELECTRONIC
FULL-TEXT FORMAT)
<6> Stahl SM et al. Brain
circuits determine destiny in depression: a novel approach to the
psychopharmacology of wakefulness, fatigue, and executive dysfunction in major
depressive disorder. [Review] [194 refs] Journal of Clinical Psychiatry. 64
Suppl 14:6-17, 2003.
<7> Stahl SM.
Deconstructing psychiatric disorders, part 2: An emerging, neurobiologically
based therapeutic strategy for the modern psychopharmacologist. Journal of
Clinical Psychiatry. 64(10):1145-6, 2003 Oct.
<8> Greenshaw AJ.
Neurotransmitter interactions in psychotropic drug action: beyond dopamine and
serotonin. Journal of Psychiatry & Neuroscience. 28(4):247-50, 2003 Jul.
<9> Mohr WK. Mohr BD.
Brain, behavior, connections and implications: psychodynamics no more. [Review]
[83 refs] Archives of Psychiatric Nursing. 15(4):171-81, 2001 Aug.
Top
